» Articles » PMID: 19503109

Quantitative Monitoring of Multi-donor Chimerism: a Systematic, Validated Framework for Routine Analysis

Overview
Specialty General Surgery
Date 2009 Jun 9
PMID 19503109
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Despite therapeutic advantages, double-donor (DD) HSCTs present technical problems for molecular chimerism (CHM) monitoring. These DD chimeras contain three matched DNAs, so that the genomes of donor(s) and recipient often share the same alleles. In the STR assay, shared recipient/donor alleles are common and have identical physico-chemical properties. As a consequence of the latter, they co-migrate in the same band ('shared peak'), which prevents measuring each allele separately. Without individual allelic measurements, the direct calculation of the chimeric recipient/donor DNA ratio is precluded. This is the first study to document and systematically examine these problems. Its goal was to provide a validated framework for accurate, routine monitoring based on a stepwise analytic paradigm for approximating percent CHM (%CHM) from shared STR-alleles. Analysis of STR-DNA from DD loci showed that at least four of six alleles were typically shared. Despite such extensive allelic sharing, we show how simple arithmetic procedures can be applied for standardized calculation of %CHM based on peak measurements. Criteria for selecting loci suitable for such analysis are provided. Validation of the computational results required analyzing 18 'informative' loci with pre-established reference values for %CHM. In all cases, the results for %CHM, calculated from peak measurements, were +/-5% of the reference value. The conclusions of the study are as follows: (1) Multi-donor chimeras, with shared alleles, can be accurately and simply analyzed within the usual limits of STR measurement error; (2) by examining these various facets of DD CHM analysis, this novel study has provided a basis for standardized, routine quantitative monitoring using the STR/VNTR assay.

Citing Articles

Solid tumor transmission from donor to recipient after allogeneic stem cell transplantation: it is rare but it happens!.

Tsirigotis P, Spyridonidis A, Gkirkas K, Chondropoulos S, Rondogianni P, Thomopoulos T Blood Transfus. 2023; 21(5):437-440.

PMID: 37146299 PMC: 10497390. DOI: 10.2450/BloodTransfus.498.


Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation?.

Yang Y, Wang X, Qin Y, Wan L, Jiang Y, Wang C Chronic Dis Transl Med. 2017; 1(1):48-54.

PMID: 29062987 PMC: 5643789. DOI: 10.1016/j.cdtm.2015.02.004.


Heterogeneous Niche Activity of Ex-Vivo Expanded MSCs as Factor for Variable Outcomes in Hematopoietic Recovery.

Kim J, Lee H, Choi H, Kim J, Chu I, Leem S PLoS One. 2016; 11(12):e0168036.

PMID: 28030562 PMC: 5193420. DOI: 10.1371/journal.pone.0168036.


Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

McCune J, Bemer M Clin Pharmacokinet. 2015; 55(5):525-50.

PMID: 26563168 PMC: 4824666. DOI: 10.1007/s40262-015-0339-2.


The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation.

Ebrahimi M, Aghdami N Int J Organ Transplant Med. 2014; 1(4):157-69.

PMID: 25013581 PMC: 4089239.